According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
A new charity football team in Peterborough has been set up to honour the memory of Jordan Smith and raise awareness of ...
Reed Atamian Reed Atamian FORT LAUDERDALE, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Reed Atamian, President of Atamian Honda, ...
Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
According to Lively, Baldoni also allegedly launched a “social manipulation” campaign to destroy her career and reputation.
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
An international study has identified two types of these so-called dysbioses in cystic fibrosis. They display ... Landmark Study Involving Babies in Ireland Supports Use of Cystic Fibrosis Drug in ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
SION-2851 is under development for the treatment of cystic fibrosis. It is a small molecule administered orally. It is a first generation corrector. The drug candidate targets cystic fibrosis ...
GlobalData on MSN10d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warningsVertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
LCI proves valuable in monitoring ETI therapy effectiveness for cystic fibrosis patients with minimal FEV1 changes, detecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback